Tessera Therapeutics develops gene writing technology designed to modify DNA sequences within human cells for therapeutic use.
Tessera Therapeutics's investors include Bill & Melinda Gates Foundation, Cormorant Asset Management, Qatar Investment Authority, SoftBank Vision Fund, Artis Ventures.
Tessera Therapeutics is headquartered in Cambridge, United States.
Tessera Therapeutics develops gene writing technology designed to modify DNA sequences within human cells for therapeutic use.
Tessera Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tessera Therapeutics — Funding & Investors." VCBacked, March 23, 2026, https://www.vcbacked.co/company/tessera-therapeutics. Accessed August 13, 2026.
VCBacked. (2026). Tessera Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/tessera-therapeutics
{{cite web |title=Tessera Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tessera-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated